title: Tough cell to investors. Venture capitalists are wary of investing in companies in which risks in the science may not be rewarded by a health revenue stream.
authors: Nuala
authors: N
authors: Moran
mesh_terms: D001709:Biotechnology / Q000191:economics*; D002140:California; D033041:Embryo Research / Q000191:economics* / Q000941:ethics / Q000331:legislation & jurisprudence; D005312:Fetal Blood / Q000166:cytology; D006801:Humans; D007221:Industry / Q000191:economics*; D013234:Stem Cells